Embed Size (px)
Citation preview
Imed
ex11675 R
ainw
ater Drive, Su
ite 600A
lph
aretta, GA
30009, USA
Early registration discounts available. Register today!Visit W
WW
.WO
RLDG
ICA
NCER.CO
M or call +1 (800) 233-0957
Registration discounts are available. Register today!Visit w
ww
.AdvancesInIBD
.com or call +1 (678) 242-0906
WWW.ADVANCESINIBD.COM
CONTINUING EDUCATIONPHYSICIANS
Imedex designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent
of their participation in the activity.
MAINTENANCE OF CERTIFICATION (MOC)Successful completion of this CME activity enables a participant to earn up to 20.75 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.
This live activity is jointly provided by Imedex®, LLC and American Academy of CME, Inc.
CNE PROVIDERAmerican Academy of CME, Inc, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
American Academy of CME, Inc. designates this educational activity for 20.67 contact hours. Please check onsite for pharmacotherapeutic contact hours.
WHO SHOULD ATTENDThis educational activity is specifically designed for gastroenterologists, hospitalists, internal medicine specialists, (physicians-in-training, advanced practice nurses, nurses, pharmacists, physician assistants) and other healthcare professionals involved and/or interested in the therapeutic management of patients with IBD.
OBJECTIVESCLINICAL TRACK
Upon successful completion of the clinical track, participants should be better able to:
• Apply a multidisciplinary patient-centered approach to IBD care
• Assess the current standards of practice in IBD management
• Summarize the role of endoscopy and the various modalities used to assess patients with IBD
• Evaluate the expanding clinical role of emerging therapies in IBD
• Discuss the surgical management of IBD, including controversial issues that impact surgical practice
• Identify patient-related factors affecting IBD management
• Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD
• Describe key aspects of healthcare reform to preserve optimal patient care
SURGICAL TRACK
Upon successful completion of the surgical track, participants should be better able to:
• Assess controversial surgical issues for IBD and apply appropriate post- treatment follow-up
NURSING AND ADVANCED PRACTICE TRACK
Upon successful completion of the nursing and advanced practice track, participants should be better able to:
• Discuss the multidisciplinary management of IBD to enhance patient outcomes
PEDIATRICS TRACK
Upon successful completion of the pediatrics track, participants should be better able to:
• Summarize the role of diet in pediatric patients with IBD, including the latest data and recommendations for special nutritional therapies, probiotics and complementary therapy
• Plan strategies to manage contraception and pregnancy in adolescents with IBD
W W W . A D V A N C E S I N I B D . C O M
NO
VEM
BER 9-11, 2017 | O
RLAN
DO
, FLORID
AW
ALT D
ISNEY
WO
RLD D
OLPH
IN H
OTEL
REGISTRATION
PhysiciansPhD and PharmD
Nurse Practitioner/Physician Assistant/Nurses/Residents/
Fellows/Students*Industry
Early: Paid by September 14, 2017
$449 $324 $175
$700Discounted: Paid by October 26, 2017
$549 $424 $200
Regular/Onsite: Paid after October 26, 2017
$649 $524 $225
ACG Member Discount* -$100
How To Register: You may register online at www.advancesinibd.com or by calling Imedex at +1 (800) 233 0957 (international callers please call +1 (678) 242 0906). For assistance, please contact [email protected]. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: Registration fees must be remitted by credit card or wire transfer. Participant is not registered until full payment is received. Fees include admittance to all scientific sessions, activity materials, processing of certificates of participation or continuing education credit, and all event functions as specified in the agenda.
IMPO
RTA
NT D
ATES
Early Reg
istration
Septem
ber 1
4, 2
01
7
Ab
stract No
tificatio
ns M
ailedSep
temb
er 15
, 20
17
Ab
stract Presen
ter Reg
istration
Dead
line
Octo
ber 2
0, 2
01
7
Disco
un
ted R
egistratio
n D
eadlin
eO
ctob
er 26
, 20
17
Presen
tation
Dates
No
vemb
er 9-1
1, 2
01
7
Clinically-relevant data and practices
that directly impact IBD
patient care.
WWW.ADVANCESINIBD.COM
NOVEMBER 9–11, 2017 | ORLANDO, FLORIDAWALT DISNEY WORLD DOLPHIN HOTEL
AIBD2017
Multidisciplinary Approaches to IBD Patient-Centered Care
BOWEL DISEASES ADVANCES in INFLAMMATORY
ENDORSED BY
NOVEMBER 9-11, 2017 | ORLANDO, FLORIDA
NEW PRESENTERS, NEW CONTENT, A NEW YEARThe management of IBD is rapidly evolving. In terms of practice guidelines, choice of therapy, and diagnostic and surgical techniques, never before have so many options been available for use in clinical practice. As such, healthcare professionals like yourself need opportunities to learn about, reinforce, and share their experiences with the latest, most important, and clinically-relevant data and practices that directly impact patient care.
Held on November 9-11, 2017 in Orlando, Florida, the 2017 Advances in Inflammatory Bowel Diseases conference is designed to be the premier event that meets the growing educational needs of healthcare professionals and researchers who study and manage patients with inflammatory bowel diseases.
Over the course of three intensive days, clinicians (including physicians, advanced practice providers, nurses, and pharmacists) will gain practice-changing knowledge and develop and share best practices in multidisciplinary care that can be implemented immediately. Additionally, surgeons will observe and gain insight into the latest advances and techniques, while researchers will stay abreast of the evolving scientific landscape.
From education to new research to networking, AIBD|2017 provides everything you need to improve the care of your IBD patients and advance your career in the field.
ADVANCES in INFLAMMATORY
BOWEL DISEASES
AIBD2017Multidisciplinary Approaches to IBD Patient-Centered Care
HAVE QUESTIONS? WE CAN HELP. Email us at: [email protected]
Or, call us at: +1 (800) 233-0957
CONFERENCE ORGANIZER
11675 Rainwater Drive, Suite 600, Alpharetta, GA 30009, USA Tel.: +1 (770) 751 7332 Fax: +1 (770) 751 7334 Email: [email protected]
/company/imedex /imedex /ImedexCME www.imedex.com
SUPPORTThe following companies support this Conference through educational grants:
Celgene Corporation
Medtronic
Pfizer
Salix Pharmaceuticals, Inc., A Division of Valeant Pharmaceuticals North America LLC
Takeda Pharmaceuticals U.S.A., Inc
UCB, Inc.
Support options are available to companies interested in participating in this conference. Please contact Imedex by email at [email protected]..
AD
VAN
CES in INFLA
MM
ATORY
BOW
EL DISEA
SES
AIBD2017
AIBD2017
Multidisciplinary Approaches
to IBD Patient-Centered CareM
ultidisciplinary Approaches to IBD Patient-Centered Care
AD
VAN
CES in INFLA
MM
ATORY BO
WEL D
ISEASES
AIBD2017
Multidisciplinary Approaches
to IBD Patient-Centered Care
AD
VAN
CES in INFLA
MM
ATORY BO
WEL D
ISEASES
AIBD2017
Multidisciplinary Approaches
to IBD Patient-Centered Care
AD
VAN
CES in INFLA
MM
ATORY BO
WEL D
ISEASES
AIBD2017
Multidisciplinary Approaches
to IBD Patient-Centered Care
AD
VAN
CES in INFLA
MM
ATORY BO
WEL D
ISEASES
AIBD2017
Multidisciplinary Approaches
to IBD Patient-Centered Care
AD
VAN
CES in INFLA
MM
ATORY
BOW
EL DISEA
SES
AIBD2017
AIBD2017
AIBD2017
AIBD2017
AIBD2017
EXHIBITIONThe following companies are Exhibitors at this Conference:
DIAMOND EXHIBITOR
PLATINUM EXHIBITOR
a division of Valeant Pharmaceuticals North America
GOLD EXHIBITOR
SILVER EXHIBITOR
CONTRIBUTOR EXHIBITOR
INTRODUCTORY EXHIBITOR
Exhibit space is available to companies interested in participating in this conference through exhibition. For more information, please contact Imedex:
Stacy S. Brandau [email protected] | +1 (404) 384-8416
Official Media Partner of AIBD|2017.
CONFERENCE LOCATION AND HOTEL ACCOMMODATIONS
For the convenience of participants, a discounted room block is available at the newly renovated Walt Disney World Dolphin Hotel at the discounted rate of $205* single/double occupancy, plus 12.5% tax until October 9, 2017. To receive the group rate, callers must identify themselves as attending the 2017 Advances in IBD conference.
To reserve your room please visit www.swandolphin.com/groupres/IMDEX7 or contact the Walt Disney World Dolphin Hotel reservations department at +1 (800) 227 1500. International guests please call +1 (407) 934 4000.
*Mandatory Resort Package: The mandatory resort package of $20 (exclusive of taxes) per room per day is included in the room rate.
Groups: If you are bringing a group of 5 or more people, you must go through Imedex for housing. Please contact Teresa Lovich at [email protected] or +1 (214) 679 8736.
Ideally located, the Walt Disney World Dolphin Hotel provides an extraordinary backdrop for business or pleasure. Nestled between lush landscape, beautiful waterways and unique architecture, the Walt Disney World Dolphin Hotel creates an impressive landmark. You will embark upon their stunning lobby and unique restaurants while enjoying the many comforts provided as one of their guests.
ADVANCES in INFLAMMATORY
BOWEL DISEASESMultidisciplinary Approaches to IBD Patient-Centered Care
Walt Disney World Dolphin Hotel 1500 Epcot Resorts Boulevard Lake Buena Vista, Florida 32830 Tel.: +1 (407) 934 4000 www.swandolphin.com
EXPERIEN
CE TH
E U
PDATED
RO
OM
S, LO
BB
Y, AN
D M
ORE!
Disco
un
ted ro
om
rates available
to A
IBD
|20
17
attend
ees
SCIENTIFIC AGENDA
Follow the AIBD|2017 Conference on Social Media! @IBDConference /AdvancesInIBD W W W . A D V A N C E S I N I B D . C O M
FACULTYFaten N. Aberra, MD, MSCE University of Pennsylvania Philadelphia, Pennsylvania
Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
Anita Afzali, MD, MPH, FACG The Ohio State University Wexner Medical Center Columbus, Ohio
John I. Allen, MD, MBA, FACG University of Michigan Ann Arbor, Michigan
Ashwin N. Ananthakrishnan, MBBS, MD, MPH Massachusetts General Hospital Boston, Massachusetts
Jean H. Ashburn, MD Cleveland Clinic Foundation Cleveland, Ohio
Leonard Baidoo, MD, FACG Northwestern University Feinberg School of Medicine Chicago, Illinois
Willem Bemelman, MD Academisch Medisch Centrum-Universiteit Van Amsterdam Amsterdam, Netherlands
Meenakshi Bewtra, MD, PhD, MPH University of Pennsylvania Philadelphia, Pennsylvania
David G. Binion, MD, FACG University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Anne Bobb, BSN, RN Penn State Health Hershey, Pennsylvania
Ashley A. Bochenek, AA, BSN, MSN University of Chicago Medicine Chicago, Illinois
Nilesh Chande, MD Victoria Hospital London, Canada
Adam S. Cheifetz, MD, FACG Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
Russell D. Cohen, MD, FACG University of Chicago Medicine Chicago, Illinois
Jean-Frederic Colombel, MD Icahn School of Medicine at Mount Sinai New York, New York
Raymond K. Cross, Jr., MD, MS University of Maryland Baltimore, Maryland
Andre D’Hoore, MD, PhD University Hospital Gasthuisberg Leuven, Belgium
Silvio Danese, MD, PhD Humanitas Clinical and Research Center Milano, Italy
David Dietz, MD Cleveland Clinic Foundation Cleveland, Ohio
Marla Dubinsky, MD Icahn School of Medicine at Mount Sinai New York, New York
Francis A. Farraye, MD, MSc, FACG Boston University School of Medicine Boston, Massachusetts
Brian G. Feagan, MD, FACG Robarts Clinical Trials Inc Western University London, Canada
Philip Fleshner, MD Cedars-Sinai Medical Center Los Angeles, California
Anne Griffiths, MD The Hospital for Sick Children University of Toronto Toronto, Canada
Stephen B. Hanauer, MD, FACG Northwestern University Feinberg School of Medicine Chicago, Illinois
Peter D. Higgins, MD, PhD, MSc University of Michigan Ann Arbor, Michigan
Jason K. Hou, MD, MS, FACG Baylor College of Medicine Michael E. Debakey VA Medical Center Houston, Texas
David P. Hudesman, MD NYU Inflammatory Bowel Disease Center New York, New York
Neil H. Hyman, MD University of Chicago Medicine Chicago, Illinois
Kim L. Isaacs, MD, PhD, FACG University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Sunanda V. Kane, MD, MSPH, FACG Mayo Clinic Rochester Rochester, Minnesota
Seymour Katz, MD, MACG NYU Langone Medical Center New York, New York
Laurie A. Keefer, PhD Icahn School of Medicine at Mount Sinai New York, New York
Maureen Kelly, APN, MS, PNP University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Sandra C. Kim, MD Children’s Hospital of Pittsburgh University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Asher Kornbluth, MD Icahn School of Medicine at Mount Sinai New York, New York
Paulo G. Kotze, MD Pontificia Universidade Catolica do Parana Curitaba, Brazil
L. Campbell Levy, MD Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire
Gary R. Lichtenstein, MD, FACG University of Pennslyvania Philadelphia, Pennsylvania
Amy L. Lightner, MD Mayo Clinic Rochester Rochester, Minnesota
Edward V. Loftus, Jr., MD, FACG Mayo Clinic Rochester Rochester, Minnesota
Millie D. Long, MD, MPH, FACG University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Richard P. MacDermott, MD, MACG Emeritus Professor of Medicine Albany Medical Center Albany, New York
Gil Y. Melmed, MD, FACG Cedars-Sinai Medical Center Los Angeles, California
Pamela J. Morgan, BSN, RN Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio
Alan C. Moss, MD, FACG Harvard Medical School Boston, Massachusetts
Mark T. Osterman, MD, MSCE University of Pennsylvania Philadelphia, Pennsylvania
Shivani Patel, PharmD University of Chicago Medicine Chicago, Illinois
Sonia Ramamoorthy, MD, FACS, FASCRS University of California San Diego Health San Diego, California
Miguel D. Regueiro, MD, FACG University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Feza Remzi, MD NYU Langone Medical Center New York, New York
David T. Rubin, MD, FACG University of Chicago Medicine Chicago, Illinois
Michele Rubin, MSN, APN, CNS, CGRN University of Chicago Medicine Chicago, Illinois
Javier P. Salgado, MD University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
William J. Sandborn, MD, FACG University of California San Diego San Diego, California
Bruce E. Sands, MD, MS, FACG Icahn School of Medicine at Mount Sinai New York, New York
Marc B. Schwartz, MD University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Bo Shen, MD, FACG Cleveland Clinic Cleveland, Ohio
Corey A. Siegel, MD, MS Dartmouth-Hitchcock Medical Center Geisel School of Medicine at Dartmouth Lebanon, New Hampshire
Siddharth Singh, MD, MBBS, MS University of California San Diego San Diego, California
Scott Strong, MD Northwestern Medicine Chicago, Illinois
David Suskind, MD Seattle Children’s Hospital Seattle, Washington
Eva Szigethy, MD, PhD, FACG University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Andrew Tinsley, MD Penn State Health Hershey, Pennsylvania
Lauren K. Tormey, MD Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire
Thomas A. Ullman, MD, FACG Mount Sinai Doctors Faculty Practice New York, New York
Fernando S. Velayos, MD, MPH University of California San Francisco San Francisco, California
Daniel von Allmen, MD Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio
Betty J. White, MN, NP-C, ARNP Digestive Health Specialists Maple Valley, Washington
Douglas C. Wolf, MD, FACG Atlanta Gastroenterology Associates Atlanta, Georgia
NOVEMBER 9-11, 2017 | ORLANDO, FLORIDA
CLINICAL TRACK
THURSDAY, NOVEMBER 9, 201711:55 AM - 2:00 PM
SESSION IA: THE MULTIDISCIPLINARY, PATIENT CENTERED APPROACH TO IBD CARE
• Rationale for a multidisciplinary, patient-centered approach to IBD care
• Management of psycho-social issues for IBD patients and their families
• The multidisciplinary surgical approach to IBD patient care
• The pediatric-adult transition: How to bridge the change
• Novel approaches to improve caregiver-patient interactions using integrated models
• Panel discussion
12:30 PM - 4:40 PM
SESSION IIA: THE CHANGING HEALTHCARE LANDSCAPE
• Will changes in healthcare legislation impact IBD patient care?
• How can the caregiver better navigate medication choice and cost hurdles?
• What should medical centers and administrators do in order to optimize patient care in our complex environment
• Advances in information technology that will improve patient care: Electronic medical records, the internet, social media, telemedicine, and remote video-medicine
• What we can learn from the European Crohn’s and Colitis Organization’s approaches to IBD Education and IBD Guidelines
• Panel discussion
5:10 PM - 7:00 PM
SESSION IIIA: NEW AND EMERGING THERAPEUTIC APPROACHES FOR IBD
• The treatment of moderate to severe IBD with anti-TNF biologics and immunomodulators
• Optimizing adhesion molecule-based therapies
• Understanding the use of IL12/IL23 targeted biologics
• Future IBD therapies
• Panel discussion
FRIDAY, NOVEMBER 10, 20177:55 AM - 10:00 AM
SESSION IVA: MAKING THE CHOICE OF THERAPY FOR CROHN’S DISEASE: HOW EVIDENCE IMPACTS PRACTICE
• Presentation on Cochrane reviews
• Presentation #1A: Use of anti-TNF therapies for Crohn’s disease
• Presentation #1B: Cases with debate and discussion
• Presentation #2A: Vedolizumab as a treatment for Crohn’s Disease: Efficacy and safety
• Presentation #2B: Cases with debate and discussion
• Presentation #3A: Ustekinumab as a treatment for Crohn’s disease: Efficacy and safety
• Presentation #3B: Cases with debate and discussion
10:30 AM - 12:30 PM
SESSION VA: CASE DISCUSSIONS IN IBD
• Case Discussion I: Management of infections in IBD patients on immunomodulators and/or biologics
• Case Discussion II: Challenges in the care of the pregnant IBD patient
• Case Discussion III: When and how to modify IBD therapies: Increasing, maintaining or de-escalating biologics and/or immunomodulators; Future use of combination biologics
• Case Discussion IV: Controversies in the surgical management of complicated Crohn’s disease
2:00 PM - 3:45 PM
SESSION VIA: CASE-BASED CLINICAL BREAKOUT SESSIONS
A. The outpatient with severe, refractory Crohn’s disease, who failed prior biologics: Case studies
B. Extra-intestinal manifestations of IBD: Case studies
C. Challenges in the surgical management of severe, refractory ulcerative colitis: Case studies with videos
D. Sexual Dysfunction in IBD: Case studies
E. Treating IBD patients with stress, anxiety, and/or depression: Case studies
F. When should the asymptomatic or mildly symptomatic IBD patient be treated? Case studies
4:20 PM - 6:20 PM
SESSION VIIA: DECIPHERING AN IBD OPERATIVE REPORT: WHAT EVERY GASTROENTEROLOGIST SHOULD KNOW
• Small bowel resection/stricturoplasty
• Ileocolic resection
• Ileal pouch-anal anastomosis
• Failing ileal J pouch
• Perianal abscess and fistula
• Panel discussion
SATURDAY, NOVEMBER 11, 20177:55 AM - 10:00 AM
SESSION VIIIA: ADVANCES IN ENDOSCOPY FOR IBD
• Use of endoscopy to evaluate esophageal, gastric, and duodenal Crohn’s disease (videos)
• How to access and determine the severity and complications of small bowel Crohn’s disease (videos)
• Using endoscopy to assess mucosal healing in “Treating to Target” for IBD (videos)
• Diagnosis and management of dysplasia and polyps in chronic ulcerative colitis (videos)
• Modalities used to evaluate the differential diagnosis of refractory pouchitis (videos)
• Panel discussion
10:30 AM - 12:30 PM
SESSION IXA: PATIENT-RELATED FACTORS AFFECTING IBD MANAGEMENT
• Caring for the patient with multiple co-morbidities
• The use of complementary and alternative medications
• Overlooked issues that will optimize the health of our patients
• Prevention and management of side effects of therapies during pregnancy and postpartum
• How to treat chronic pain and avoid narcotic dependence
• Panel discussion
2:00 PM - 3:45 PM
SESSION XA: CASE-BASED CLINICAL BREAKOUT SESSIONS
A. Challenging IBD patients with concurrent liver disease: Case studies
B. Treatment of complicated ulcerative colitis patients following surgery: Case studies with videos
C. Managing IBD patients with a prior or current malignancy: Case studies
D. Recognizing and managing side effects due to medications used to treat IBD: Case studies
E. Reassessing immunomodulators: Which patient, which drug, and which dose: Case studies
F. Use of therapeutic endoscopic techniques to manage complications of Crohn’s disease
4:15 PM - 5:55 PM
SESSION XIA: PROGRESS IN IBD PATIENT CARE
• Defining an IBD patient’s disease severity and prognosis
• Therapeutic drug monitoring: When, why, and how
• Challenges in treating the elderly patient with IBD
• Clostridia difficile in IBD
• Panel discussion
NURSING & ADVANCED PRACTICE TRACK
FRIDAY, NOVEMBER 10, 20177:55 AM - 10:00 AM
SESSION IVB: INTERPROFESSIONAL IBD PATIENT MANAGEMENT
• 10 things every IBD nurse and advanced practice clinician should know
• The nurse’s role in interprofessional “treat to target” patient care
• Child and parental coping strategies
• J-Pouch assessment, management, and surveillance: Strategies by an interprofessional team
10:30 AM - 12:30 PM
SESSION VB: CASE PRESENTATIONS AND INTERACTIVE DISCUSSION
• Joint pains: Are they IBD or arthritis related?
• “Helicopter parents”: How to manage using a interprofessional team
• Risk and benefits of cannibis for IBD patients
• Adjusting to a new J-Pouch and managing pouchitis/cuffitis
SURGICAL TRACK
SATURDAY, NOVEMBER 11, 20177:55 AM - 10:00 AM
SESSION VIIID: DEBATES IN IBD SURGERY
• Debate 1: The best technique for ileal pouch surgery: Top to bottom vs. Bottom to top
• Discussion, synthesis, and consensus
• Debate 2: The best permanent stoma in IBD patients: End vs. Continent ileostomy
• Discussion, synthesis, and consensus
• Debate 3: Do biologics heal anal fistulas? Definitely vs. Absolutely not
• Discussion, synthesis, and consensus
10:30 AM - 12:30 PM
SESSION IXD: CHALLENGES IN IBD SURGERY
• When should a mucosectomy IPAA be done instead of a stapled IPAA?
• How to optimally use robotics in IBD surgery
• Can stem cell therapy treat Crohn’s disease fistulae?
• Does the choice of surgical technique impact recurrence rates following ileocolic resection for Crohn’s disease?
• What sphincter preserving operations can be performed in patients with large bowel Crohn’s disease?
• Panel discussion
PEDIATRIC TRACK
FRIDAY, NOVEMBER 10, 20174:15 PM - 6:35 PM
SESSION VIIC: PROGRESS IN PEDIATRIC IBD
• Pediatric IBD clinical year in review
• Advances in the use of nutrition for therapy in pediatric Crohn’s disease
• What are the challenges we face for pediatric patients who need surgery?
• Case discussion: Challenges of self-image, sexuality; contraception and pregnancy in adolescents with IBD
• Panel discussion: Complex pediatric IBD cases
• Case 1: Management of the hospitalized UC patient (Items to address include infectious sequelae – C. difficile; CMV; Medication dosing with high dose infliximab; Surgical timing)
• Case 2: Management of the patient with complicated Crohn’s disease
ADVANCES in INFLAMMATORY
BOWEL DISEASES
AIBD 2017Multidisciplinary Approaches to IBD Patient-Centered Care
REGISTRATION AND DISCOUNTED HOTEL RESERVATIONSRegister and reserve your hotel rooms at W W W. A DVA N C E S I N I B D. CO M
